The purpose of the study is to check whether giving cloxacillin through continuous infusion maintains proper levels of the medication in the blood. This is important to ensure that patients receive enough medication to fight the infection without getting too much that could cause harmful effects. The study will monitor the amount of active medication in the blood at different times during treatment.

During the study, patients will receive cloxacillin continuously through the pump for up to 6 weeks. Blood samples will be taken at several points during the first two days of treatment to measure medication levels. The total daily dose of medication will be between 6 and 12 grams, delivered steadily throughout each 24-hour period.

The treatment being tested includes two investigational products, PP1493 and PP1815, which are bacteriophage solutions given through intra-articular injection (injection directly into the joint). These will be compared to a placebo treatment, with both groups also receiving standard surgical care. The study aims to determine if adding bacteriophage therapy to standard treatment is safe and effective for treating prosthetic joint infections.

The study will monitor patients for three months to assess their response to treatment. Participants will receive either the bacteriophage treatment or placebo, along with standard care. During the study, doctors will track the healing of the infection and monitor for any side effects. The treatment period lasts for three days, with follow-up evaluations continuing for several months to ensure patient safety and assess treatment effectiveness.

Participants in the study will receive either the single dose of Dalbavancin or the standard antibiotics. The study will monitor the participants for 30 days to check for signs of infection and ensure the infection does not return. The study will also look at other factors such as the time it takes for the infection to clear from the blood, the duration of hospital stays, and any side effects experienced by the participants.

The study aims to provide valuable information on whether a single dose of Dalbavancin can be a simpler and effective alternative to the longer standard antibiotic treatments for catheter-related bloodstream infections caused by Staphylococcus aureus. This could potentially lead to shorter treatment times and fewer hospital visits for patients in the future.

Participants in the study will receive Teicoplanin through inhalation at a dose of 200 mg twice a day. The treatment will be given in two cycles, each lasting 28 days, with a 28-day break in between the cycles. The study will monitor the participants’ health and any side effects they may experience during and after the treatment cycles. The goal is to ensure that the medication is safe and to observe how it affects the bacterial infection in the lungs.

Throughout the study, various health checks will be conducted to assess lung function and the presence of the bacteria in the lungs. These checks will help determine if the treatment is effective in reducing the bacterial load and improving lung health. The study will also look at any changes in symptoms such as coughing, chest tightness, and breathing difficulties. The information gathered will contribute to understanding how well Teicoplanin works for treating these infections in cystic fibrosis patients.

Participants in the study will receive cloxacillin through an intravenous route, meaning it will be administered directly into a vein. The study will monitor patients over a period of time to see how well the drug works and to check for any potential side effects. The researchers will pay special attention to how the drug levels relate to kidney function and whether patients reach the desired drug concentration in their blood. This will help in understanding if the standard dosing needs to be adjusted based on individual kidney function.

Throughout the study, various health markers will be observed, including any signs of kidney damage or changes in mental status, such as confusion or tremors. The study will also consider factors like age, weight, and other health conditions that might affect the treatment. By gathering this information, the study aims to improve the way cloxacillin is used to treat Staphylococcus aureus bacteremia, ensuring it is both safe and effective for patients with different levels of kidney function.

The purpose of the study is to evaluate how effective this combination treatment is in managing infections associated with joint prostheses over a period of 12 months after surgery. Participants in the study will receive the treatment and be monitored for any signs of the infection returning or not improving. The study will also look at how well patients tolerate the medications by checking for any side effects during the treatment period.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on the success of the treatment. The main goal is to determine if the combination of dalbavancin and rifampicin can effectively prevent the failure of the treatment within a year after surgical management of the infection. Additionally, the study will assess the treatment’s success over a longer period of 24 months and monitor any adverse effects experienced by the participants.